

## DAFTAR PUSAKA

1. Zhou Z, Cui Y, Wu J, Ding R, Cai T, Gao Z. “*Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia*”. BMC Urology (2019); 19:17. Doi: 10.1186/s12894-019-0446-8
2. Fawzi A, Kamel M, Salem E et al. “*Sildenafil citrate in combination with tamsulosin versus tamsulosin monotherapy for management of male lower urinary tract symptoms due to benign prostatic hyperplasia: A randomised, double-blind, placebo-controlled trial*”. Arab J Urol (2016). Doi: 10.1016/j.aju.2016.11.001
3. Tjahjohadi, Soebadi DM, Umbas R et al. “*Pedoman Penatalaksanaan Klinis Pembesaran Prostat Jinak (Benign Prostatic Hyperplasia / BPH)*. 3<sup>rd</sup> ed”. Indonesian Urological Association. Jakarta: Indonesian Urological Association (2015). 1-27
4. Qiangzhao L, Xiaofeng Z, Fenghai Z et al. “*Efficacy and tolerability of combination therapy with alpha-blockers and phosphodiesterase-5 inhibitors compared with monotherapy for lower urinary tract symptoms*”. Medicine (2020); 99:43. Doi: 10.1097/MD.00000000000022834
5. Ma C, Zhang J, Cai Z, Xiong J, Li H. “*Defining the Efficacy and Safety of Phosphodiesterase Type 5 Inhibitors with Tamsulosin for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia with or without Erectile Dysfunction: A Network Meta-Analysis*”. BioMed Research International (2020). Doi: 10.1155/2020/1419520
6. Wang XH, Wang X, Shi MJ, Li S, Liu T, Zhang SH. “*Systematic review and meta-analysis on phosphodiesterase 5 inhibitors and  $\alpha$ -adrenoceptor antagonists used alone or combined for treatment of LUTS due to BPH*”. Asian Journal of Andrology (2015); 17:1022–1032. Doi: 10.4103/1008-682X.154990
7. Gravas S, Cornu JN, Gacci M et al. “*EAU Guidelines on Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO)*”. Netherland : European Association of Urology Guidelines (2021)
8. Dunn CJ, Matheson A, Faulds DM. “*Tamsulosin : A Review of its Pharmacology and Therapeutic Efficacy in the Management of Lower Urinary Tract Symptoms*”. Drugs Aging (2002); 19 (2): 135-161. Doi: 1170-229X/02/0002-0135

9. Gacci M, Corona G, Salvi M et al. "A Systematic Review and Meta-analysis on the Use of Phosphodiesterase 5 Inhibitors Alone or in Combination with  $\alpha$ -Blockers for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia". *European Urology* (2012); 61(5): 994-1003. Doi: 10.1016/j.eururo.2012.02.033
10. Nehikhare O, Kasivisvanathan V, Ellis H, Challacombe B. "Anatomy, Physiology and Pathology of The Large Prostate". *The Big prostate*. London: Springer international publishing AG (2018); 1-15. Doi: 10.1007/978-3-319-64704-3\_1
11. Chughtai B, Forde JC, Thomas DDM et al. "Benign Prostatic Hyperplasia". *Nature Reviews Disease Primer*. New York : Macmillan Publishers Limited (2016). Doi: 10.1038/nrdp.2016.31
12. Agur AMR, Dalley AF. "Grant's Atlas of Anatomy 13<sup>th</sup> ed". Philadelphia: Lippincott Williams & Wilkins, a Wolters Kluwer (2013). P 227-30
13. Roehrborn CG. "Benign Prostatic Hyperplasia: an Overview". *Reviews in Urology* (2005); 7 (9): S3-S14. PMID: PMC1477638
14. Ng M, Baradhi KM. "Benign Prostatic Hyperplasia". StatPearls Publishing LLC. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK558920/>
15. Roehrborn CG. "Pathology of Benign Prostatic Hyperplasia". *International Journal of Impotence Research* (2008); 20 : S11-S18. Doi: 10.1038/ijir.2008.55
16. Foster CS. "Pathology of Benign Prostatic Hyperplasia". *The Prostate Supplement* (2000); 9: 4-14. Doi: 10.1002/1097-0045(2000)45:9+<4::AID-PROS3>3.0.CO;2-Q
17. Lee CL, Kuo HC. "Patophysiology of benign prostate enlargement and lower urinary tract symptoms: Current concepts". *Tzu Chi Medical Journal* (2017); 29(2): 79-83. Doi: 10.4103/tcmj.tcmj\_20\_17
18. Kim SW, Park NC, Lee SW et al. "Efficacy and Safety of a Fixed-Dose Combination Therapy of Tamsulosin and Tadalafil for Patients with Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Randomized, Double-Blinded, Active-Controlled Trial". *Jornal of Sex Medicine* (2017); 14: 1018e1027. Doi: 10.1016/j.jsxm.2017.06.006
19. Bechara A, Romano S, Casabe A et al. "Comparative Efficacy Assessment of Tamsulosin vs. Tamsulosin Plus Tadalafil in the Treatment of LUTS/BPH. Pilot Study". *Jornal of Sex Medicine* (2008); 5: 2170-2178. Doi: 10.1111/j.1743-6109.2008.00940.x

20. Yan H, Zong H, Cui Y, Li N, Zhang Y. "The Efficacy of PDE5 Inhibitors Alone or in Combination with Alpha-Blockers for the Treatment of Erectile Dysfunction and Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis". *Jornal of Sex Medicine* (2014); 11(6): 1539-1545. Doi: 10.1111/jsm.12499
21. Lee SN, Chakrabarty B, Wittmer B et al. "Age Related Differences in Responsiveness to Sildenafil and Tamsulosin are due to Myogenic Smooth Muscle Tone in the Human Prostate". *Scientific Reports* (2017); 7: 10150. Doi:10.1038/s41598-017-07861-x
22. Sebastianelli A, Spatafora P, Morselli S et al. "Tadalafil Alone or In Combination with Tamsulosin for the Management for LUTS/BPH and ED". *Current Urology Reports* (2020); 21: 56. Doi: 10.1007/s11934-020-01009-7
23. Regardas RP, Reges R, Cerqueira JBG et al. "Urodynamic Effects of the Combination of Tamsulosin and Daily Tadalafil in Men with Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: a Randomized, Placebo-Controlled Clinical Trial". *International Urology and Nephrology* (2013); 45:39-43. Doi: 10.1007/s11255-012-0317-7
24. Takeda M, Yokoyama O, Yoshida M et al. Safety and Efficacy of The Combination of Once-Daily Tadalafil and Alpha-1 Blocker in Japanese Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: A randomized, Placebo-Controlled, Cross-Over Study". *International Journal of Urology* (2017); 24(7):539-547. Doi: 10.1111/iju.13357
25. Dahlan MS. "Langkah-Langkah Membuat Proposal Penelitian Bidang Kedokteran dan Kesehatan, Ed 2". Jakarta: Sagung Seto (2012)
26. Roehrborn CG, Strand DW. "Benign Prostatic Hyperplasia : Etiology, Pathophysiology, and Natural History". *Campbell-Walsh-Weinn Urology* 12<sup>th</sup> ed. Philadelphia : Elsevier (2021)
27. Nagasubramanian S, John NT, Antonisamy B et al. "Tamsulosin and placebo vs tamsulosin and tadalafil in male lower urinary tract symptoms: a double-blinded, randomised controlled trial ". *BJU International* (2020); 125:718–724. Doi: 10.1111/bju.15027
28. Angulo J, Cuevas P, Fernandez A et al. "Tadalafil Enhances the Inhibitory Effects of Tamsulosin on Neurogenic Contractions of Human Prostate and Bladder Neck". *Journal of Sexual Medicine* (2012); 9:2293–2306. Doi: 10.1111/j.1743-6109.2012.02821.x

29. Oger S, Roussel DB, Gorny D et al. "Combination of Alfuzosin and Tadalafil Exerts In Vitro an Additive Relaxant Effect on Human Corpus Cavernosum". *Journal of Sexual Medicine* (2008); 5:935–945. Doi: 10.1111/j.1743-6109.2007.00754.x
30. Sun K, Sun F, Yao H et al. "Efficacy and Safety of Combination Comprising Tamsulosin and PDE5-Is, Relative to Monotherapies, in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction Associated with Benign Prostatic Hyperplasia: A Meta-Analysis". *American Journal of Men's Health* (2020); 14(6). Doi: 10.1177/1557988320980180
31. Zhang J, Li X, Yang B et al. "Alpha-blockers with or without phosphodiesterase type 5 inhibitor for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis". *World Journal of Urology* (2019); 37(1):143-153. Doi: 10.1007/s00345-018-2370-z
32. Ligouri G, Trombetta C, Giorgi GD et al. "Efficacy and Safety of Combined Oral Therapy with Tadalafil and Alfuzosin: An Integrated Approach to the Management of Patients with Lower Urinary Tract Symptoms and Erectile Dysfunction. Preliminary Report". *Journal of Sexual Medicine* (2009); 6:544–552. Doi: 10.1111/j.1743-6109.2008.01109.x
33. Seftel AD, Farber J, Fletcher J et al. "A three-part study to investigate the incidence and potential etiologies of tadalafil-associated back pain or myalgia". *International Journal of Impotence Research* (2005); 17:455–461. Doi:10.1038/sj.ijir.3901374

